Compositions methods and systems for pulmonary delivery of recombinant human interferon alpha-2b
US6830744B2 · kind B2 · utility
0Cited by
10References
34Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | May 31, 2002 |
| Grant date | Dec 14, 2004 |
| Priority date | — |
| Expiry date | May 31, 2022 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K9/19
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Stable aqueous formulations which are free of products derived from human or animal origin and which maintain high biological activity and high chemical and physical stability of alpha-type interferon for an extended period of time. Methods of producing stable aerosol formulations of the same for delivery to the lungs are also provided, as well as systems and methods of delivering the formulations to the lungs for systemic absorption.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.